Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Neldaleucel by Marker Therapeutics for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Neldaleucel is under clinical development by Marker Therapeutics and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to...
Data Insights
Neldaleucel by Marker Therapeutics for CNS Lymphoma: Likelihood of Approval
Neldaleucel is under clinical development by Marker Therapeutics and currently in Phase I for CNS Lymphoma. According to GlobalData, Phase...